Digital transformation of mental health services

This paper makes a case for digital mental health and provides insights into how digital technologies can enhance (but not replace) existing mental health services. We describe digital mental health by presenting a suite of digital technologies (from digital interventions to the application of artificial intelligence). We discuss the benefits of digital mental health, for example, a digital intervention can be an accessible stepping-stone to receiving support. The paper does, however, present less-discussed benefits with new concepts such as ‘poly-digital’, where many different apps/features (e.g. a sleep app, mood logging app and a mindfulness app, etc.) can each address different factors of wellbeing, perhaps resulting in an aggregation of marginal gains. Another benefit is that digital mental health offers the ability to collect high-resolution real-world client data and provide client monitoring outside of therapy sessions. These data can be collected using digital phenotyping and ecological momentary assessment techniques (i.e. repeated mood or scale measures via an app). This allows digital mental health tools and real-world data to inform therapists and enrich face-to-face sessions. This can be referred to as blended care/adjunctive therapy where service users can engage in ‘channel switching’ between digital and non-digital (face-to-face) interventions providing a more integrated service. This digital integration can be referred to as a kind of ‘digital glue’ that helps join up the in-person sessions with the real world. The paper presents the challenges, for example, the majority of mental health apps are maybe of inadequate quality and there is a lack of user retention. There are also ethical challenges, for example, with the perceived ‘over-promotion’ of screen-time and the perceived reduction in care when replacing humans with ‘computers’, and the trap of ‘technological solutionism’ whereby technology can be naively presumed to solve all problems. Finally, we argue for the need to take an evidence-based, systems thinking and co-production approach in the form of stakeholder-centred design when developing digital mental health services based on technologies. The main contribution of this paper is the integration of ideas from many different disciplines as well as the framework for blended care using ‘channel switching’ to showcase how digital data and technology can enrich physical services. Another contribution is the emergence of ‘poly-digital’ and a discussion on the challenges of digital mental health, specifically ‘digital ethics’.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g.means) or other basic estimates (e.g.regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g.Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection n/a Data analysis n/a For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers.We strongly encourage code deposition in a community repository (e.g.GitHub).See the Nature Portfolio guidelines for submitting code & software for further information.

Data Policy information about availability of data
All manuscripts must include a data availability statement.This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy Provide your data availability statement here.

nature portfolio | reporting summary
April 2023

Antibodies Antibodies used
Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.

Validation
Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

Eukaryotic cell lines
Policy information about cell lines and Sex and Gender in Research Cell line source(s) State the source of each cell line used and the sex of all primary cell lines and cells derived from human participants or vertebrate models.

Authentication
Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination
Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).Permits should encompass collection and, where applicable, export.

Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods
If new dates are provided, describe how they were obtained (e.g.collection, storage, sample pretreatment and measurement), where they were obtained (i.e.lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other research organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals
For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.Field-collected samples For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

nature portfolio | reporting summary
April 2023

Design specifications
Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
Behavioral performance measures State number and/or type of variables recorded (e.g.correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g.mean, range, and/or standard deviation across subjects).

Specify in Tesla
Sequence & imaging parameters Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

Area of acquisition
State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined. Diffusion

Volume censoring
Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

Statistical modeling & inference
Model type and settings

Graph analysis
Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject-or group-level, and the global and/or node summaries used (e.g.clustering coefficient, efficiency, etc.).
Multivariate modeling and predictive analysis Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.
NormalizationIf data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
CorrectionDescribe the type of correction and how it is obtained for multiple comparisons (e.g.FWE, FDR, permutation or Monte Carlo).Report the measures of dependence used and the model details (e.g.Pearson correlation, partial correlation, mutual information).
Specify type(mass univariate, multivariate, RSA, predictive, etc.)and describe essential details of the model at the first and second levels (e.g.fixed, random or mixed effects; drift or auto-correlation).(SeeEklundet al. 2016)Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.